Mainz Biomed NV (MYNZ) is now in the Overvalued zone, suggesting that its current forward PS ratio of 10.62 is considered Overvalued compared with the five-year average of -2.52. The fair price of Mainz Biomed NV (MYNZ) is between 0.34 to 0.66 according to relative valuation method. Compared to the current price of 0.84 USD , Mainz Biomed NV By Overvalued By 27.45%.

Relative Value

Fair Zone

0.34-0.66

Current Price：0.84

27.45%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Mainz Biomed NV (MYNZ) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Mainz Biomed NV (MYNZ) has a current Price-to-Book (P/B) ratio of 1.88. Compared to its 3-year average P/B ratio of 4.16, the current P/B ratio is approximately -54.79% higher. Relative to its 5-year average P/B ratio of 5.83, the current P/B ratio is about -67.71% higher. Mainz Biomed NV (MYNZ) has a Forward Free Cash Flow (FCF) yield of approximately -155.13%. Compared to its 3-year average FCF yield of -174.61%, the current FCF yield is approximately -11.15% lower. Relative to its 5-year average FCF yield of -120.80%, the current FCF yield is about 28.42% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for MYNZ competitors is 1.77, providing a benchmark for relative valuation. Mainz Biomed NV Corp (MYNZ.O) exhibits a P/S ratio of 10.62, which is 500% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of MYNZ increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of MYNZ in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is MYNZ currently overvalued or undervalued?

What is Mainz Biomed NV (MYNZ) fair value?

MYNZ's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Mainz Biomed NV (MYNZ) is between 0.34 to 0.66 according to relative valuation method.

How does MYNZ's valuation metrics compare to the industry average?

The average P/S ratio for MYNZ's competitors is 1.77, providing a benchmark for relative valuation. Mainz Biomed NV Corp (MYNZ) exhibits a P/S ratio of 10.62, which is 500.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Mainz Biomed NV (MYNZ) as of Mar 04 2026?

As of Mar 04 2026, Mainz Biomed NV (MYNZ) has a P/B ratio of 1.88. This indicates that the market values MYNZ at 1.88 times its book value.

What is the current FCF Yield for Mainz Biomed NV (MYNZ) as of Mar 04 2026?

As of Mar 04 2026, Mainz Biomed NV (MYNZ) has a FCF Yield of -155.13%. This means that for every dollar of Mainz Biomed NV's market capitalization, the company generates -155.13 cents in free cash flow.

What is the current Forward P/E ratio for Mainz Biomed NV (MYNZ) as of Mar 04 2026?

As of Mar 04 2026, Mainz Biomed NV (MYNZ) has a Forward P/E ratio of -0.55. This means the market is willing to pay $-0.55 for every dollar of Mainz Biomed NV's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Mainz Biomed NV (MYNZ) as of Mar 04 2026?

As of Mar 04 2026, Mainz Biomed NV (MYNZ) has a Forward P/S ratio of 10.62. This means the market is valuing MYNZ at $10.62 for every dollar of expected revenue over the next 12 months.

MYNZ Valuation